Paxlovid does not increase risk of COVID reinfection: study

Published Date: 16 Feb 2023

Although there are concerns that the use of Paxlovid increases the risk of COVID-19 returning, the results are clear.

Read Full News

Latest News

Fact vs. Fallacy: Challenging the Norms of Cancer Care

Dr Bishal Gyawali explores why lowering the bar for drug approvals is a fallacy and why asking for better evidence is a sign of patient advocacy, not an attack on innovation.

The Alcohol-Sugar Double Whammy Coming to Patients Near You

Highly sweetened alcoholic drinks may amplify liver risk by combining concentrated alcohol exposure with metabolic stress.

Exam Rooms Front Line in Fight Against Youth Vaping

Exam rooms are becoming a critical and increasingly complex front line in preventing adolescent nicotine addiction.

Occupational PTSD Typically Affects UK Men More Than Women

A 28-year surveillance study in the UK showed that occupational posttraumatic stress disorder most frequently affected men, with police and military personnel at the highest risk.

CAR-T Therapy Shows Promise in CNS and Extramedullary B-ALL

A retrospective study evaluates the effectiveness of CD19 CAR T-cell therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with extramedullary or CNS disease.

Reassuring Data for Two High-Efficacy MS Meds in Pregnancy

Two longitudinal studies showed no adverse safety signals associated with prenatal exposure to two high-efficacy drugs for MS.

Todays Updates

Psychotropics Linked to Increased BMI, CVD Risk

Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Todays Updates

Psychotropics Linked to Increased BMI, CVD Risk

Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Latest News

Dr Bishal Gyawali explores why lowering the bar for drug approvals is a fallacy and why asking for better evidence is a sign of patient advocacy, not an attack on innovation.

Highly sweetened alcoholic drinks may amplify liver risk by combining concentrated alcohol exposure with metabolic stress.

Exam rooms are becoming a critical and increasingly complex front line in preventing adolescent nicotine addiction.

A 28-year surveillance study in the UK showed that occupational posttraumatic stress disorder most frequently affected men, with police and military personnel at the highest risk.

A retrospective study evaluates the effectiveness of CD19 CAR T-cell therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with extramedullary or CNS disease.

Two longitudinal studies showed no adverse safety signals associated with prenatal exposure to two high-efficacy drugs for MS.

News All Time

Is Venetoclax Retreatment Effective in Relapsed CLL?

Researchers review available clinical evidence for retreatment with venetoclax, alone or in combination, in patients with relapsed chronic lymphocytic leukemia.

For Farmers, Mental Health Care That Fits

Two recently launched initiatives endorse ‘farm-informed therapy’ to support mental health in the prairie provinces.

Genetic Testing for Kidney Disease Often Not Discussed

A survey found that clinicians are not discussing genetic testing with 80% of patients with kidney disease who meet established clinical criteria.

Prenatal Vitamin D Linked to Modest Gains in Child Memory

High-dose vitamin D3 supplementation during pregnancy may improve memory in children.

Is Pregnancy Safe for Women With Myasthenia Gravis?

Pregnancy does not increase the risk for exacerbations of myasthenia gravis, but the postpartum period is associated with a higher risk for prolonged hospital stays for exacerbations.

Docs Say Patients Are Losing Trust in Their Advice: Survey

In a new Medscape survey of 400 US physicians, nearly half said their patients have less trust in their treatment recommendations. See the key findings from the survey.

Don't Blame COVID for Diabetes 'Surge' in Kids

The prevalence of type 2 diabetes is rising among US youth, and if we don’t address the real causes, we really will see a potentially unstoppable surge.

How to Boost CRC Screening Uptake in the Community

Programs that support patients in the screening process or mail stool test kits to their homes are most effective at boosting colorectal cancer screening rates.

Global Outbreaks and Travel Vaccination Update

From rabid seals off South Africa to urban Anopheles stephensi in Africa, shifting vectors and outbreaks mean clinicians must update travel vaccine counseling and pretravel immunization plans.

Endometriosis Linked to Raised Breast & Ovarian Cancer Risks

Women with endometriosis or adenomyosis face a higher risk for breast cancer and ovarian cancer than those without these conditions.

HCV Antiviral Moves Toward EU Use in Acute Infection

European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.

Cataract Surgery: 4 Things You Might Not Know

From mythical thorn bushes to flying aces, the remarkable history of one of medicine’s most routine procedures.

Managing the Second Victim in Healthcare

After a patient safety incident, clinicians need confidential, empathetic, and nonpunitive support — not blame — to prevent burnout and silence, reduce repeat errors, and improve reporting and care quality.

Reduced JAK Inhibitor Dosing May Not Compromise RA Outcomes

In patients with rheumatoid arthritis and preserved kidney function, reduced initial doses of JAK inhibitors show 2-year treatment persistence and disease control similar to those with standard doses.

Tofacitinib May Have Beneficial Effect on JIA Patient Growth

According to a post hoc analysis of patients with juvenile idiopathic arthritis on tofacitinib, younger patients have higher height velocities than expected, and older patients have normal velocities.

What a PA Retirement Wave May Mean for Healthcare Access

As more PAs consider retirement, some areas of the country may face shortages, resulting in worse access to healthcare.

Recommended News For You

Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

The pandemic had little impact on mental health symptoms.

Gene therapy and chemotherapy may be combined in novel ways to treat bone cancer.

Do I qualify for a cancer clinical trial?

Dual-action mRNA vaccine takes aim at aggressive skin cancer

Study sheds light on challenges for women of color after breast cancer surgery

Recommended Articles For You

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies 

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025 

Understanding Vaso Occlusive Crisis: Symptoms, Causes, and Management Strategies 

All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

2.

Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.

3.

New tumor therapy approach reduces costs and side effects while increasing accessibility

4.

Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.

5.

Pollution exposure may affect lung cancer in women who have never smoked

1.

The Mysterious World of Petechiae: Exploring Causes and Treatments

2.

IGSF8: A Rising Star in Cancer Immunotherapy - Harnessing the Innate Immune System

3.

Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology

4.

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer

5.

Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

2.

Navigating the Complexities of Ph Negative ALL - Part XIV

3.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

4.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

5.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot